A non-government resource for the Medicare community
Powered by Q1Group LLC
A non-government Medicare community resource
  • Menu
  • Home
  • Contact
  • MAPD
  • PDP
  • 2024
  • 2025
  • FAQs
  • Articles
  • Search
  • Contact
  • 2024
  • 2025
  • FAQs
  • Articles
  • Latest Medicare News
  • Search

CMS Notice of Release of Intermediate Sanctions (Suspension of Marketing and Enrollment) for Medicare Advantage-Prescription Drug and Prescription Drug Plan contract numbers: H2020, H2334, H3071, H5454, H6379, H6672, H8293, H9403, H9589, and S6946

Category: Medicare Plan Providers
Published: Sep, 22 2020 03:09:43


Update: September 22, 2020  The Centers for Medicare & Medicaid Services (CMS) has release the Intermediate Sanctions (Suspension of Marketing and Enrollment) for Medicare Advantage-Prescription Drug and Prescription Drug Plan contract numbers: H2020, H2334, H3071, H5454, H6379, H6672, H8293, H9403, H9589, and S6946 administered by Delaware Life Insurance Company (DLIC).

The CMS notice of release states,
"Based on the results of the validat ion audit, CMS has determined that DLIC’s deficiencies have been sufficiently corrected. Therefore, effective September 22, 2020, CMS is lifting the intermediate sanctions for contracts H2020, H2334, H3071, H5454, H6379, H6672, H8293, H9403 H9589, and S6946 and DLIC will return to normal marketing and enrollment status."

Original Article February 2, 2020
CMS imposes Intermediate Sanctions (Suspension of Enrollment and Marketing) on Medicare Advantage-Prescription Drug and Prescription Drug Plan contract numbers: H2020, H2334, H3071, H5454, H6379, H6672, H8293, H9403, H9589, and S6946

On January 31, 2020, the Centers for Medicare and Medicaid Services (CMS) gave notice to Delaware Life Insurance Company (DLIC) that CMS has made a determination to impose immediate intermediate sanctions on the following Medicare Advantage- Prescription Drug (MA-PD) and Prescription Drug Plan (PDP) Contract Numbers: H2020, H2334, H3071, H5454, H6379, H6672, H8293, H9403, H9589, and S6946.

CMS noted that "[s]ince January 1, 2020, DLIC has experienced widespread system failures with its enrollment operations, which have resulted in a disruption to its beneficiaries’ access to prescription medications.  CMS has determined that these operational deficiencies have resulted in the substantial failure to comply with DLIC’s MA-PD and PDP contracts and warrant the imposition of intermediate sanctions."

The sanctions will consist of the suspension of enrollment of Medicare beneficiaries into DLIC’s contract and the suspension of all marketing activities to Medicare beneficiaries. These intermediate sanctions went into effect on January 31, 2020.


From the CMS notification letter:

"On January 3, 2020, DLIC informed CMS that it had identified several issues with its MA-PD and PDP contracts which included:

(1) failing to process enrollment transactions on time,
(2) failing to send member identification (ID) cards and other enrollment documents to enrollees, and
(3) call center wait times exceeding CMS standard time-frames.

At the same time, CMS began to see an influx of complaints through its complaints tracking module (CTM) from enrollees who were complaining that DLIC had no record of their enrollment transactions and they were in need of medications.

Based on these issues, CMS immediately became concerned and contacted DLIC for more information.

Prior to 2020, DLIC operated seven MA-PD contracts to administer Part C and D benefits to approximately 5,300 beneficiaries. For contract year 2020, DLIC decided to offer a new stand-alone prescription drug benefit (i.e. Part D) and added two MA-PD contracts. This new PDP contract provided favorable premium and benefit options for enrollees, which made it eligible to receive low-income subsidy (LIS) enrollees.

At the same time, DLIC’s enrollment processing vendor moved the organization onto a new enrollment platform and understaffed its enrollment department based on understated membership projections. However, by January 1, 2020, DLIC’s enrollment increased by over 1,000% and, at the same time, enrollment processing issues began to arise.

To date, CMS has received over 160 complaints in its CTM from DLIC beneficiaries. CMS analysis of these CTMs show numerous complaints where beneficiaries are being told that they are not enrolled in DLIC even though they have confirmation numbers showing that they should be enrolled in the plan. In some cases, beneficiaries are being informed by the pharmacy that they are not enrolled in the plan while trying to pick up their medications.

In other cases, beneficiaries are complaining that they have not received ID cards and have had to pay out of pocket for medications. In addition, DLIC disclosed over 400 grievances have not been addressed. DLIC has not fully analyzed and provided details about the nature of these grievances to CMS. In addition, when beneficiaries call into DLIC to try to resolve the enrollment or other issues, they are being placed on hold for significant periods of time.1

DLIC has offered several reasons for why there were breakdowns in processing thousands of enrollments. However, DLIC has yet to provide CMS with comprehensive explanations for why some of these errors occurred and whether the issues have been resolved.



These errors have caused DLIC’s pharmacy network to have inaccurate membership status information for enrollees. As a result, DLIC is seeing rejected claims at the point of service that are related to eligibility and enrollment issues. In addition, there were a number of data errors that caused ID cards and welcome kits not to be mailed to beneficiaries timely. As of January 20, 2020 there were still hundreds of ID cards and welcome kits that were not mailed.2

Of greatest concern is that CMS is not confident that DLIC has fully reconciled its enrollment with its vendors to determine which members should be enrolled in DLIC and/or whether the member is enrolled in the correct plan. DLIC has admitted that it is not fully aware of all of the root causes that contributed to the enrollment system failures. Therefore, CMS concludes that DLIC has not yet fully diagnosed the extent of its current failures or all of the enrollees that require remediation, which is critical to the development and execution of an effective corrective action plan.

In addition to the above enrollment issues, DLIC also admitted that its Pharmacy Benefit Manager uploaded a file containing errors with its pharmacy network which were visible to its enrollees and prospective enrollees on Medicare Plan Finder during the Annual Election Period. As a result, beneficiaries enrolled into DLIC with the expectation that their pharmacy was in the network. These beneficiaries are now attempting to fill prescriptions at their pharmacies and are being turned away because their pharmacy is not in the DLIC network." [formatting added]

----------------------------

1
Hold times appear to be decreasing, however, DLIC stated it anticipates that it will not meet CMS call center requirements until February.

2
DLIC has not provided clear details on the number of ID cards and welcome kits that remain outstanding.


Read the CMS notice:

"Notice of Imposition of Immediate Intermediate Sanctions (Suspension of Enrollment and Marketing) for Medicare Advantage-Prescription Drug and Prescription Drug Plan contract numbers: H2020, H2334, H3071, H5454, H6379, H6672, H8293, H9403, H9589, and S6946" 
 https://www.cms.gov/files/ document/dlicsanction01312020.pdf


Related FAQs about Sanctioned Medicare plans:









Tips & Disclaimers
  • Q1Medicare®, Q1Rx®, and Q1Group® are registered Service Marks of Q1Group LLC and may not be used in any advertising, publicity, or for commercial purposes without the express authorization of Q1Group.
  • The Medicare Advantage and Medicare Part D prescription drug plan data on our site comes directly from Medicare and is subject to change.
  • Medicare has neither reviewed nor endorsed the information on our site.
  • We provide our Q1Medicare.com site for educational purposes and strive to present unbiased and accurate information. However, Q1Medicare is not intended as a substitute for your lawyer, doctor, healthcare provider, financial advisor, or pharmacist. For more information on your Medicare coverage, please be sure to seek legal, medical, pharmaceutical, or financial advice from a licensed professional or telephone Medicare at 1-800-633-4227.
  • We are an independent education, research, and technology company. We are not affiliated with any Medicare plan, plan carrier, healthcare provider, or insurance company. We are not compensated for Medicare plan enrollments. We do not sell leads or share your personal information.
  • Benefits, formulary, pharmacy network, provider network, premium and/or co-payments/co-insurance may change on January 1 of each year. Our PDPCompare.com and MACompare.com provide highlights of annual plan benefit changes.
  • The benefit information provided is a brief summary, not a complete description of benefits. For more information contact the plan.
  • Limitations, copayments, and restrictions may apply.
  • We make every effort to show all available Medicare Part D or Medicare Advantage plans in your service area. However, since our data is provided by Medicare, it is possible that this may not be a complete listing of plans available in your service area. For a complete listing please contact 1-800-MEDICARE (TTY users should call 1-877-486-2048), 24 hours a day/7 days a week or consult www.medicare.gov.
    Statement required by Medicare:
    "We do not offer every plan available in your area. Any information we provide is limited to those plans we do offer in your area. Please contact Medicare.gov or 1-800-MEDICARE to get information on all of your options."
  • When enrolling in a Medicare Advantage plan, you must continue to pay your Medicare Part B premium.
  • Medicare beneficiaries with higher incomes may be required to pay both a Medicare Part B and Medicare Part D Income Related Monthly Adjustment Amount (IRMAA). Read more on IRMAA.
  • Medicare Advantage plans that include prescription drug coverage (MAPDs) are considered Medicare Part D plans and members with higher incomes may be subject to the Medicare Part D Income Related Monthly Adjustment Amount (IRMAA), just as members in stand-alone Part D plans. In certain situations, you can appeal IRMAA.
  • You must be enrolled in both Medicare Part A and Part B to enroll in a Medicare Advantage plan. Members may enroll in a Medicare Advantage plan only during specific times of the year. Contact the Medicare plan for more information.
  • If you are enrolled in a Medicare plan with Part D prescription drug coverage, you may be eligible for financial Extra Help to assist with the payment of your prescription drug premiums and drug purchases. To see if you qualify for Extra Help, call: 1-800-MEDICARE (1-800-633-4227). TTY users should call 1-877-486-2048, 24 hours a day/ 7 days a week or consult www.medicare.gov; the Social Security Office at 1-800-772-1213 between 7 a.m. and 7 p.m., Monday through Friday. TTY users should call, 1-800-325-0778; or your state Medicaid Office.
  • Medicare evaluates plans based on a 5-Star rating system. Star Ratings are calculated each year and may change from one year to the next.
  • A Medicare Advantage Private Fee-for-Service plan (PFFS) is not a Medicare supplement plan. Providers who do not contract with the plan are not required to see you except in an emergency.
  • Disclaimer for Institutional Special Needs Plan (SNP): This plan is available to anyone with Medicare who meets the Skilled Nursing Facility (SNF) level of care and resides in a nursing home.
  • Disclaimer for Dual Eligible (Medicare/Medicaid) Special Needs Plan (SNP): This plan is available to anyone who has both Medical Assistance from the State and Medicare. Premiums, co-pays, co-insurance, and deductibles may vary based on the level of Extra Help you receive. Please contact the plan for further details.
  • Disclaimer for Chronic Condition Special Needs Plan (SNP): This plan is available to anyone with Medicare who has been diagnosed with the plan specific Chronic Condition.
  • Medicare MSA Plans combine a high deductible Medicare Advantage Plan and a trust or custodial savings account (as defined and/or approved by the IRS). The plan deposits money from Medicare into the account. You can use this money to pay for your health care costs, but only Medicare-covered expenses count toward your deductible. The amount deposited is usually less than your deductible amount, so you generally have to pay out-of-pocket before your coverage begins.
  • Medicare MSA Plans do not cover prescription drugs. If you join a Medicare MSA Plan, you can also join any separate (stand-alone) Medicare Part D prescription drug plan
  • There are additional restrictions to join an MSA plan, and enrollment is generally for a full calendar year unless you meet certain exceptions. Those who disenroll during the calendar year will owe a portion of the account deposit back to the plan. Contact the plan provider for additional information.
  • Medicare beneficiaries may enroll through the CMS Medicare Online Enrollment Center located at www.medicare.gov.
  • Medicare beneficiaries can file a complaint with the Centers for Medicare & Medicaid Services by calling 1-800-MEDICARE 24 hours a day/7 days or using the medicare.gov site. Beneficiaries can appoint a representative by submitting CMS Form-1696.